CompDx hrHPV Genotype
(13 hrHPV types reported)
Developed by the doctors at CMCD, the CompDx hrHPV genotype is like no other test offered today. CompDx simultaneously tests for and reports genotype data for 13 hrHPV types*. This allows CompDx hrHPV to be a powerful tool when working with high risk populations where hrHPV 16 and 18 may not be prevalent, especially in minority population.
Reporting each of the 13 genotypes helps the physician better determine the difference between a transient, or non-relevant, infection and a persistent infection. Thereby it may reduce the need for Colposcopy in patients with negative Pap but a positive hrHPV result.
The United States Preventative Service Task Force (USPTF) recommends screening women ages 21 to 65 years with cytology every 3 years or, for women ages 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and HPV testing every 5 years.
An independent study by CMCD of prevalent hrHPV types indicates that type 16 or 18 exist in 20% of all cases; co-infection in 17%. In CIN1 and above pap, 16, 18 exist in 19% as single types and 27% as multiple types. Multiple types account for 27% of all cases.